Infectious Disease Alert – July 1, 2013
July 1, 2013
View Issues
-
Azithromycin – The Heart of the Matter Redux: Preexisting Risks Tell the Tale
The risk of cardiovascular mortality with current use of the azalide (but not with past or future use) was increased (rate ratio, 2.85; 95% CI 1.13 to 7.24). -
Get our new physician’s guide by filling out IDA reader survey
-
Infection Risks of Pandemic H1N1 Flu, Measles during Air Travel
Two recent studies from the Centers for Disease Control and Prevention evaluated the risks for spread of respiratory viruses from travelers on commercial airplanes. -
Early use of Daptomycin Compared to Vancomycin for MRSA Bacteremia
In a matched, retrospective cohort study, early use of daptomycin compared to vancomycin in MRSA bacteremia with vancomycin MICs > 1 ìg/mL resulted in improved clinical outcomes, including less clinical failure at 30 days, lower mortality and less persistent bacteremia. -
Update: MERS-CoV Continues to Strike
The novel coronavirus which emerged in the Middle East, now officially called MERS-CoV (Middle East respiratory syndrome coronavirus), has continued to cause new, often fatal infections. As of June 7, 2013, there have been 55 laboratory-confirmed cases of infection worldwide, according to the Centers for Disease Control and Prevention. -
Serious Infections in Travelers
More than three-fourths of these serious infections were due to Plasmodium falciparum, followed at some distance by typhoid and paratyphoid fever, and by leptospirosis and a variety of other infections. -
Updates
Snooping out counterfeit anti-malarials; Teflon to some; Rethinking TB screening in a low risk population -
Pharmacology Watch: Is Naproxen the Safest NSAID for the Heart?
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions. -
Clinical Briefs in Primary Care supplement